Ocotea (Ocotea odorifera)

Ocotea (Ocotea odorifera) is an Amazonian tree whose essential oil is rich in safrole and methyleugenol, phenylpropanoid compounds that drive its anti-inflammatory and antimicrobial properties. These compounds inhibit pro-inflammatory pathways and disrupt microbial membrane integrity, supporting its traditional use in South American herbalism.

Origin & History

Ocotea odorifera is an evergreen tree native to southern Brazil, known commonly as 'canela-sassafrás'. Its leaves and branches are used to prepare decoctions, ethanolic extracts, and essential oils through hydrodistillation.

Historical & Cultural Context

Traditionally, Ocotea odorifera has been used in southern Brazilian folk medicine to treat inflammatory conditions, rheumatism, and skin diseases. Its use is supported by ethnopharmacological documentation and preclinical findings (PMID: 32918995; PMID: 20922478).

Health Benefits

• Anti-inflammatory effects demonstrated in mouse models (PMID: 32918995).
• Enhances antibiotic efficacy against MDR bacterial strains in vitro (PMID: 34656506).
• Exhibits antifungal activity, particularly against Candida parapsilosis (PMID: 20922478).
• Contains phenolic compounds with antioxidant activity (PMID: 28407959).
• Low cytotoxicity, indicating potential safety in preclinical assessments (PMID: 20922478).

How It Works

Ocotea odorifera's primary bioactives, safrole and methyleugenol, modulate inflammatory signaling by inhibiting NF-κB activation and suppressing COX-2-mediated prostaglandin synthesis, as demonstrated in mouse models. Its phenolic constituents also disrupt fungal and bacterial cell membrane permeability, impairing efflux pump function in multidrug-resistant (MDR) strains and potentiating conventional antibiotic activity. Antioxidant effects are attributed to free radical scavenging by flavonoids and hydroxycinnamic acid derivatives present in bark and leaf extracts.

Scientific Research

There are no human clinical trials or meta-analyses for Ocotea odorifera. The evidence is limited to preclinical studies, such as in vivo anti-inflammatory assays in mice (PMID: 32918995) and in vitro antibacterial assays (PMID: 34656506).

Clinical Summary

Current evidence for Ocotea odorifera is limited to in vitro and animal studies, with no published human clinical trials. A mouse model study (PMID: 32918995) demonstrated significant reduction in inflammatory markers following essential oil administration. In vitro research (PMID: 34656506) showed that Ocotea extracts reduced minimum inhibitory concentrations of antibiotics against MDR bacterial strains, and antifungal testing (PMID: 20922478) confirmed activity against Candida parapsilosis with measurable MIC values. The evidence base is preliminary and insufficient to establish efficacy or dosing recommendations for humans.

Nutritional Profile

{"macronutrients": {"fiber": "Not specifically quantified, but present in moderate amounts typical of plant materials."}, "micronutrients": {"vitamins": {"Vitamin C": "Trace amounts, typical of plant-based sources."}, "minerals": {"Calcium": "Trace amounts, typical of plant-based sources.", "Magnesium": "Trace amounts, typical of plant-based sources."}}, "bioactive_compounds": {"Phenolic compounds": {"Concentration": "Approximately 0.5-1.5 mg/g", "Bioavailability": "Moderate, influenced by matrix effects and gut microbiota."}, "Linalool": {"Concentration": "Approximately 0.3-0.8 mg/g", "Bioavailability": "High, due to lipophilic nature and absorption in the gut."}, "Safrole": {"Concentration": "Approximately 0.1-0.3 mg/g", "Bioavailability": "Moderate, with potential metabolic conversion affecting bioactivity."}}}

Preparation & Dosage

No clinically studied dosages are available due to the absence of human trials. Preclinical models used unspecified concentrations for leaf decoctions and ethanolic fractions. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Erythromycin, Gentamicin, Nystatin, Fluconazole, Amphotericin

Safety & Interactions

Safrole, a major constituent of Ocotea odorifera essential oil, is classified as a potential carcinogen by the FDA and IARC based on hepatotoxicity and tumor promotion in rodent studies at high doses, warranting caution with prolonged or high-dose use. Ocotea is contraindicated during pregnancy and breastfeeding due to safrole's potential genotoxic effects and insufficient safety data. Theoretical drug interactions exist with CYP450-metabolized medications, particularly CYP2E1 substrates, as safrole is a known CYP2E1 inducer that could alter drug metabolism. No standardized safe dosage has been established for human supplemental use.